BridgeBio Pharma (BBIO) Other Working Capital Changes (2018 - 2026)

BridgeBio Pharma (BBIO) has 6 years of Other Working Capital Changes data on file, last reported at -$1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Working Capital Changes fell 25.99% year-over-year to -$1.9 million; the trailing twelve-month figure through Mar 2026 stood at -$6.9 million (down 19.94% YoY), and the FY2025 full-year result was -$6.5 million, down 10.93% from the prior year.
• Other Working Capital Changes fell to -$1.9 million in Q1 2026, from -$1.8 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $24.0 million in Q1 2024 to a low of -$18.6 million in Q4 2025.
• A 5-year average of $555764.7 and a median of -$313000.0 in 2025 frame the typical range for Other Working Capital Changes.
• Across the five-year window, Other Working Capital Changes slumped 36.02% in 2022 and jumped 31.32% in 2023, its largest moves.
• Tracing BBIO's Other Working Capital Changes over 5 years: stood at -$1.4 million in 2022, then gained by 18.79% to -$1.2 million in 2023, then dropped by 24.61% to -$1.4 million in 2024, then declined by 24.05% to -$1.8 million in 2025, then declined by 3.46% to -$1.9 million in 2026.
• Business Quant data shows BBIO's Other Working Capital Changes at -$1.9 million in Q1 2026, -$1.8 million in Q4 2025, and -$1.6 million in Q3 2025.